Anesthesiology, Pain Medicine · Athens, GA
NPI
1447693833
Since 2013
Specialty
Anesthesiology, Pain Medicine
Code 207LP2900X
Group practices
1
Medicare group memberships
Hospitals
1
Hospital affiliations
1000 Hawthorne Ave Ste J
Athens, GA, 30606
Phone (706) 286-8344
Groups this clinician bills Medicare through
Medicare paid, 2024
$411K
6,822 services
Medicare patients, 2024
298
Average age 70
Drug cost, 2024
$987K
16,202 prescriptions
Company payments, 2025
$453
From 8 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by James S Ashford was code 99213 (office e&m - established), 1,926 times for 270 patients. In total James S Ashford billed 6,822 services in 38 codes, and Medicare paid $411K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2024-02-26.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99213 Office E&M - Established | Office | 1,926 | 270 | $60.92 | $117K |
| 80305 Drug Tests | Office | 878 | 266 | $12.20 | $11K |
| 99490 Chronic, Principal, and Transitional Care Management | Office | 824 | 111 | $45.28 | $37K |
| 99439 Chronic, Principal, and Transitional Care Management | Office | 764 | 108 | $33.61 | $26K |
| A9585 Injection, gadobutrol, 0.1 ml | Office | 680 | 11 | $0.23 | $158 |
| G0481 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms | Office | 485 | 168 | $153.46 | $74K |
| G0482 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms | Office | 290 | 126 | $193.21 | $56K |
| 99487 Chronic, Principal, and Transitional Care Management | Office | 146 | 93 | $97.32 | $14K |
| J1885 Injection, ketorolac tromethamine, per 15 mg | Office | 100 | 16 | $0.45 | $44.9 |
| 27096 Joint Injection | Office | 90 | 62 | $158.93 | $14K |
| 99204 Office E&M - New | Office | 75 | 75 | $112.81 | $8,461 |
| 99489 Chronic, Principal, and Transitional Care Management | Office | 74 | 43 | $53.45 | $3,956 |
| G0483 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms | Office | 67 | 67 | $241.98 | $16K |
| 20610 Joint Injection | Office | 45 | 18 | $38.13 | $1,716 |
| 64490 Nerve Block Injection - Back | Office | 33 | 25 | $186.67 | $6,160 |
By year: 2022 $478K for 39,283 services; 2023 $477K for 10,352 services; 2024 $411K for 6,822 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 80305 Drug Tests | 878 | 266 | $12.20 | $11K |
| G0481 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms | 485 | 168 | $153.46 | $74K |
| G0482 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms | 290 | 126 | $193.21 | $56K |
| G0483 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms | 67 | 67 | $241.98 | $16K |
Medicare prescription drug claims, 2024
In 2024, the drug James S Ashford prescribed most often to Medicare patients was Oxycodone-Acetaminophen (Oxycodone Hcl/Acetaminophen), with 3,401 prescriptions and refills. In total James S Ashford wrote 16,202 Medicare prescriptions that cost $987K.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen | 3,401 | 3,401 | 373 | $107K |
| Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen | 3,001 | 3,001 | 360 | $77K |
| Oxycodone Hcl Generic | 1,733 | 1,735 | 198 | $32K |
| Buprenorphine Hcl Generic | 759 | 763 | 252 | $24K |
| Pregabalin Generic | 707 | 732 | 158 | $11K |
| Gabapentin Generic | 557 | 648 | 180 | $6,097 |
| Tramadol Hcl Generic | 496 | 500 | 123 | $4,323 |
| Morphine Sulfate Er Morphine Sulfate | 427 | 427 | 101 | $11K |
| Buprenorphine Generic | 385 | 385 | 190 | $101K |
| Celecoxib Generic | 360 | 391 | 121 | $13K |
| Naloxone Hcl Generic | 309 | 309 | 268 | $22K |
| Tizanidine Hcl Generic | 307 | 326 | 101 | $3,411 |
| Hydromorphone Hcl Generic | 306 | 307 | 56 | $6,027 |
| Cyclobenzaprine Hcl Generic | 290 | 302 | 110 | $1,857 |
| Baclofen Generic | 259 | 285 | 99 | $2,389 |
Brand drugs: 1,012 claims; generic drugs: 15,190 claims; opioid claims: 10,696.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid James S Ashford $453 ($453 in general payments such as food, travel and fees) from 8 companies. The largest payer was SPR Therapeutics, Inc with $103.
| Company | Payments | Amount |
|---|---|---|
| SPR Therapeutics, Inc | 1 | $103 |
| Collegium Pharmaceutical, Inc. COLL | 5 | $94.01 |
| Scilex Pharmaceuticals Inc. | 3 | $64.55 |
| Vertex Pharmaceuticals Incorporated VRTX | 2 | $48.74 |
| Globus Medical, Inc. GMED | 2 | $47.33 |
| Virtus Pharmaceuticals LLC | 2 | $37.44 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC BHC | 2 | $35.35 |
| Forte Bio-Pharma LLC | 1 | $23.35 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.